AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10369424 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (starting dose of 2.5 mg before breakfast, adjusted to 5 or 10 mg)
Number of subjects: 576
Study 10369424 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 576
Study 10369424 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 576
Study 7537355 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.25 U/kg/week)
Number of subjects: 20
Study 1974664 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (n = 16)
Number of subjects: 45
Study 1974664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 45
Study 7386740 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a nasogastric tube
Number of subjects: 300
Study 7386740 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube
Number of subjects: 300
Study 29333081 — intervention group
Group type: EXPERIMENTAL
Intervention: Innate immune cells
Number of subjects: 10
Study 29333081 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired immune cells
Number of subjects: 10
Study 29333081 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood T cells
Number of subjects: 10
Study 27263034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study 27263034 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 0
Study 27263034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol and/or Probucol
Number of subjects: 0
Study 27263034 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard statin therapy)
Number of subjects: 0
Study 25661981 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring without alarms
Number of subjects: 160
Study 25661981 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with alarms
Number of subjects: 160
Study 25661981 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose
Number of subjects: 160
Study 23816015 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-based intervention (1 household visit every 2 months for 12 months)
Number of subjects: 2438
Study 23816015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHW visits)
Number of subjects: 2438
Study 23816015 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-based intervention
Number of subjects: 2438
Study 23816015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2438
Study 20381657 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based antiplatelet and antithrombin therapies during the initial 24 hours of hospital admission
Number of subjects: 14070
Study 20381657 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital coronary angiography
Number of subjects: 14070
Study 20381657 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital outcomes
Number of subjects: 14070
Study 20381657 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 14070
Study 20381657 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 14070
Study 18403080 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0
Study 18403080 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study 18403080 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17187132 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degrees preequatorial retinal photocoagulation
Number of subjects: 35
Study 17187132 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic photocoagulation around predisposing lesions
Number of subjects: 35
Study 17187132 — intervention group
Group type: COMPARATOR
Intervention: No preoperative retinal photocoagulation
Number of subjects: 35
Study 15523399 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch 25 mg per day
Number of subjects: 70
Study 15523399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15523399 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 70
Study 11122841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy plus radiotherapy
Number of subjects: 0
Study 11122841 — intervention group
Group type: COMPARATOR
Intervention: Initial chemotherapy followed by radiation therapy (combined modality therapy)
Number of subjects: 0
Study 9065538 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF levels of tau protein in patients with AD
Number of subjects: 36
Study 9065538 — intervention group
Group type: COMPARATOR
Intervention: Normal and neurologic controls
Number of subjects: 36
Study 8320021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 30
Study 8320021 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 30
Study 3525317 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg/day, 3 days/week)
Number of subjects: 20
Study 3525317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3525317 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 20
Study 29789176 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic counseling
Number of subjects: 305
Study 29789176 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 305
Study 27100726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (1 gram in two divided doses)
Number of subjects: 43
Study 27100726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsule)
Number of subjects: 43
Study 27100726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Number of subjects: 43
Study 24886440 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face guidance strategy
Number of subjects: 27
Study 24886440 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailing strategy
Number of subjects: 27
Study 24886440 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no guidance)
Number of subjects: 27
Study 22392325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSE)
Number of subjects: 70
Study 22392325 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological methods
Number of subjects: 70
Study 20347311 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up clinic appointment two months after discharge
Number of subjects: 154
Study 20347311 — intervention group
Group type: COMPARATOR
Intervention: No appointment (control)
Number of subjects: 154
Study 18339258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone (IMP) 50 mg daily
Number of subjects: 412
Study 18339258 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal gel (VGP) 90 mg once daily
Number of subjects: 412
Study 18339258 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal gel (VGP) 90 mg twice daily
Number of subjects: 412
Study 15682477 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 79
Study 15682477 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 79
Study 12869088 — intervention group
Group type: COMPARATOR
Intervention: Quinine dihydrochloride (Qn) alone
Number of subjects: 52
Study 12869088 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine dihydrochloride (Qn) with pentoxifylline (Px) (10 mg/kg/day for 3 days)
Number of subjects: 52
Study 12869088 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine dihydrochloride (Qn) with pentoxifylline (Px)
Number of subjects: 52
Study 10941802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance exercise (jogging, walking, cycling, swimming) for 12 weeks, average of 25 min two to three times a week at 50% of VO2max
Number of subjects: 27
Study 10941802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance exercise
Number of subjects: 27
Study 10941802 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary FM patients)
Number of subjects: 27
Study 8974891 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electronic monitoring during labor
Number of subjects: 8
Study 8974891 — intervention group
Group type: COMPARATOR
Intervention: Intermittent auscultation of the fetal heart rate
Number of subjects: 8
Study 1556284 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session training group (n = 29)
Number of subjects: 60
Study 1556284 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 60
Study 2861527 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (50 mg/day)
Number of subjects: 26
Study 2861527 — intervention group
Group type: COMPARATOR
Intervention: Amiloride (5 mg/day)
Number of subjects: 26
Study 2861527 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg/day)
Number of subjects: 26
Study 2861527 — intervention group
Group type: COMPARATOR
Intervention: Triamterene-containing combination diuretic
Number of subjects: 26
Study 30901079 — intervention group
Group type: EXPERIMENTAL
Intervention: Evofinder® system
Number of subjects: 1000
Study 29193093 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning fasting (FAST; 0 kcal until 12.00 h)
Number of subjects: 49
Study 29193093 — intervention group
Group type: COMPARATOR
Intervention: Daily breakfast consumption (BFAST; ≥700 kcal before 11.00 h)
Number of subjects: 49
Study 26199116 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet provided before UDS
Number of subjects: 104
Study 26199116 — intervention group
Group type: COMPARATOR
Intervention: No information leaflet provided before UDS
Number of subjects: 104
Study 23656841 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran SR (75 mg or 100 mg)
Number of subjects: 553
Study 23656841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 21115317 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized teaching method
Number of subjects: 18
Study 21115317 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 18
Study 19356393 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release cyclobenzaprine tablet (20 mg)
Number of subjects: 36
Study 19356393 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release cyclobenzaprine tablet (20 mg) with high fat meal
Number of subjects: 36
Study 19356393 — intervention group
Group type: COMPARATOR
Intervention: Immediate release cyclobenzaprine tablet (10 mg)
Number of subjects: 36
Study 17239355 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine 20 mg
Number of subjects: 99
Study 17239355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 17239355 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine 10 mg
Number of subjects: 99
Study 15534477 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-penetrating deep sclerectomy (NPDS)
Number of subjects: 65
Study 15534477 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-Non-penetrating deep sclerectomy (phaco-NPDS)
Number of subjects: 65
Study 15534477 — intervention group
Group type: EXPERIMENTAL
Intervention: Punch trabeculectomy (PT)
Number of subjects: 65
Study 15534477 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-Punch trabeculectomy (phaco-PT)
Number of subjects: 65
Study 11119472 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients with obstructive coronary artery disease (n = 30)
Number of subjects: 83
Study 11119472 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetic patients without obstructive coronary artery disease (n = 12)
Number of subjects: 83
Study 11119472 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients with obstructive coronary artery disease (n = 28)
Number of subjects: 83
Study 11119472 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients without obstructive coronary artery disease (n = 13)
Number of subjects: 83
Study 9039834 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg betaC/d)
Number of subjects: 0
Study 9039834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8174049 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg etidronate disodium for 24 hours
Number of subjects: 30
Study 8174049 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg etidronate disodium for 24 hours
Number of subjects: 30
Study 2974417 — intervention group
Group type: EXPERIMENTAL
Intervention: procaterol
Number of subjects: 8
Study 2974417 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 31842246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (COLD)
Number of subjects: 9
Study 31842246 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study 29540217 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin once daily
Number of subjects: 6980
Study 29540217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6980
Study 28746231 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal Growth Factor (EGF)
Number of subjects: 180
Study 28746231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor-2 (FGF-2)
Number of subjects: 180
Study 28746231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% (w/v) Ofloxacin drops
Number of subjects: 180
Study 28746231 — intervention group
Group type: COMPARATOR
Intervention: Conservative observation
Number of subjects: 180
Study 26439936 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% iodopovidone
Number of subjects: 60
Study 26439936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% iodopovidone
Number of subjects: 60
Study 26439936 — intervention group
Group type: COMPARATOR
Intervention: Both doses of iodopovidone
Number of subjects: 60
Study 23399437 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8844
Study 23399437 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-colonography
Number of subjects: 8844
Study 23399437 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy non-screenees
Number of subjects: 8844
Study 23399437 — intervention group
Group type: COMPARATOR
Intervention: CT-colonography non-screenees
Number of subjects: 8844
Study 21358397 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction systems
Number of subjects: 1110
Study 21358397 — intervention group
Group type: COMPARATOR
Intervention: Open suction systems
Number of subjects: 1110
Study 18489219 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants told they would be able to smoke during the study
Number of subjects: 0
Study 18489219 — intervention group
Group type: COMPARATOR
Intervention: Participants who anticipated having to wait several hours before smoking
Number of subjects: 0
Study 21344051 — intervention group
Group type: EXPERIMENTAL
Intervention: Provent® nasal valve device
Number of subjects: 20
Study 15754270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 314
Study 15754270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 12142108 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro brain natriuretic peptide (NT-proBNP) measurement on admission
Number of subjects: 755
Study 12142108 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measurement combined with clinical background factors, ECG, and troponin T
Number of subjects: 755
Study 9519233 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose powder inhaler
Number of subjects: 10
Study 9519233 — intervention group
Group type: COMPARATOR
Intervention: Reservoir device
Number of subjects: 10
Study 8079925 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide studies
Number of subjects: 77
Study 8079925 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic studies
Number of subjects: 77
Study 8079925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radionuclide and videofluoroscopic studies
Number of subjects: 77
Study 8079925 — intervention group
Group type: COMPARATOR
Intervention: Manometry
Number of subjects: 77
Study 2511911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily plus Atenolol 50 mg twice daily
Number of subjects: 18
Study 2511911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg twice daily plus Atenolol 50 mg twice daily
Number of subjects: 18
Study 2511911 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg twice daily
Number of subjects: 18
Study 12618533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ACTH
Number of subjects: 36
Study 12618533 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ACTH
Number of subjects: 36
Study 12618533 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison subjects (control)
Number of subjects: 36
Study 31790665 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐holding a cellular phone to answer a call from investigators
Number of subjects: 47
Study 29908688 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (70 g per day)
Number of subjects: 60
Study 29908688 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (70 g per day)
Number of subjects: 60
Study 27703294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril/Hydrochlorothiazide
Number of subjects: 270
Study 24779731 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drug combinations
Number of subjects: 0
Study 24779731 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 22665030 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contacts of pediatric patients with S aureus colonization and SSTI
Number of subjects: 609
Study 22665030 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contacts (parents)
Number of subjects: 609
Study 22665030 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-resistant S aureus (MRSA)
Number of subjects: 609
Study 22665030 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-sensitive S aureus (MSSA)
Number of subjects: 609
Study 21029610 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid orally
Number of subjects: 109
Study 21029610 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + tibolone 1.25 mg/d orally
Number of subjects: 109
Study 21029610 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: osteoform 1000 mg/d + alfacalcidol 0.25 µg/bid + bisphosphonates 70 mg/w orally
Number of subjects: 109
Study 21029610 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 109
Study 21029610 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 109
Study 21029610 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 109
Study 19077238 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual auditory cueing device
Number of subjects: 47
Study 19077238 — intervention group
Group type: COMPARATOR
Intervention: Control (no auditory cueing device)
Number of subjects: 47
Study 15960573 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase dosing of escitalopram (10-20 mg/day)
Number of subjects: 27
Study 15960573 — intervention group
Group type: COMPARATOR
Intervention: Symptom-onset dosing of escitalopram (10-20 mg/day)
Number of subjects: 27
Study 12907109 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.25% bupivacaine
Number of subjects: 200
Study 12907109 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 200
Study 12907109 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study 10596559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (0.15 mg infusion 15 minutes before operation)
Number of subjects: 21
Study 10596559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clonidine (0.15 mg 60-90 minutes before operation)
Number of subjects: 21
Study 7552519 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 0
Study 7552519 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine (ddC)
Number of subjects: 0
Study 1781761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate cream 0.1% applied once daily
Number of subjects: 0
Study 1781761 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate cream 0.05% applied twice daily
Number of subjects: 0
Study 6797754 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate (0.1%)
Number of subjects: 39
Study 6797754 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (2%)
Number of subjects: 39
Study 30621789 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577
Study 29577512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT) in addition to standard treatment
Number of subjects: 80
Study 29577512 — intervention group
Group type: COMPARATOR
Intervention: Delayed CRT group
Number of subjects: 80
Study 26943500 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary oral immunonutrition (IN) (Oral Impact®, Nestlé) to reach a goal of 1.5 g protein/kg BW, administered for seven days before surgery.
Number of subjects: 35
Study 26943500 — intervention group
Group type: COMPARATOR
Intervention: Control group continued their habitual diet.
Number of subjects: 35
Study 26943500 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary oral immunonutrition (IN) (Oral Impact®, Nestlé)
Number of subjects: 35
Study 24475144 — intervention group
Group type: EXPERIMENTAL
Intervention: Souvenaid
Number of subjects: 179
Study 24475144 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 179
Study 23212429 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported depression
Number of subjects: 202
Study 23212429 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Zung Depression Index (MZDI)
Number of subjects: 202
Study 23212429 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Somatic Perception Questionnaire (MSPQ)
Number of subjects: 202
Study 23212429 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MZDI and MSPQ scores
Number of subjects: 202